A2 Biotherapeutics Advances A2B395 in Solid Tumors
AGOURA HILLS, Calif. — September 15, 2026 A2 Biotherapeutics announced encouraging early safety and efficacy findings from the ongoing...
HNSCC
Advertisement
Pyxis Oncology Advances MICVO Toward Phase 3 in HNSCC
BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...
Kenvue’s TYLENOL With Naproxen Shows Lasting Pain Relief
Fort Washington, Pennsylvania, U.S., September 8, 2026 New clinical evidence presented at PAINWeek 2026 highlights the potential of a...
Brainomix Reports Positive AI Imaging Data in IPF Trial
Oxford, United Kingdom, September 8, 2026 Brainomix and Endeavor BioMedicines have presented positive results from a quantitative image analysis...
INBRX-106 Doubles Response Rate in Phase 2 HNSCC
San Diego, California, U.S., September 8, 2026 Inhibrx Biosciences, Inc. has reported positive primary endpoint results from the randomized...
Advertisements
Inhibrx to Present INBRX-106 Phase 2 HNSCC Results
San Diego, California, USA, September 4, 2026 Inhibrx Biosciences, Inc. has announced plans to host a live webcast presentation...
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Alpha Tau Medical Ltd. Reports Positive Head and Neck Cancer Results
JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...
Advertisement
